Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mct1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous, Subcutaneous
01
Overview
mct1 siRNA refers to small interfering RNA (siRNA) designed to target and silence the expression of monocarboxylate transporter 1 (MCT1, encoded by the SLC16A1 gene). MCT1 is a proton-coupled transmembrane transporter that mediates the bidirectional transport of monocarboxylates, primarily lactate, across cell membranes. In many cancers, MCT1 is upregulated to facilitate lactate efflux, preventing intracellular acidification and promoting cell survival, proliferation, and migration (the Warburg effect). Silencing MCT1 via siRNA has been widely investigated in preclinical research to inhibit tumor growth, reverse drug resistance, and reduce liver fibrosis in metabolic diseases like nonalcoholic steatohepatitis (NASH).
- Other names
- MCT-1 siRNAMCT1 siRNAMCT 1 siRNASLC16A1 siRNASLC-16A1 siRNASLC 16A1 siRNAmonocarboxylate transporter 1 siRNAsiMCT1siMCT-1siMCT 1siRNA targeting MCT1
02
Targets
SLC16A1 (Mitochondrial Pyruvate Carrier)
Beyond the preview
Go deeper on mct1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mct1 siRNA.